Bank of America Flags $12B Clear Street IPO Risks and Cuts CVS EPS Forecasts
Bank of America analysts warned that Clear Street’s planned IPO at a $12 billion valuation faces pushback from institutional investors over pricing and demand concerns. The bank also cut its 2026 and 2027 EPS forecasts for CVS Health following fourth-quarter results, citing margin compression and softer retail growth.
1. Concern Over Clear Street IPO Valuation
Bank of America’s research team highlighted that Clear Street’s upcoming IPO targeting a $12 billion valuation has met resistance from some institutional buyers, who question whether pricing accurately reflects market demand and growth prospects in electronic trading platforms.
2. Updated CVS Health Earnings Outlook
Following CVS Health’s fourth-quarter report, Bank of America lowered its 2026 and 2027 EPS estimates, pointing to narrower pharmacy margins and slower retail segment growth as key drivers for the downward revisions.